86 related articles for article (PubMed ID: 9495252)
1. Identification of exposed epitopes on the envelope glycoproteins of human T-cell lymphotropic virus type I (HTLV-I).
Grange MP; Rosenberg AR; Horal P; Desgranges C
Int J Cancer; 1998 Mar; 75(5):804-13. PubMed ID: 9495252
[TBL] [Abstract][Full Text] [Related]
2. Identification of a neutralization epitope on the envelope gp46 antigen of human T cell leukemia virus type I and induction of neutralizing antibody by peptide immunization.
Tanaka Y; Zeng L; Shiraki H; Shida H; Tozawa H
J Immunol; 1991 Jul; 147(1):354-60. PubMed ID: 1711082
[TBL] [Abstract][Full Text] [Related]
3. Sequence variations in the amino- and carboxy-terminal parts of the surface envelope glycoprotein of HTLV type 1 induce specific neutralizing antibodies.
Tallet B; Astier-Gin T; Moynet D; Londos-Gagliardi D; Guillemain B
AIDS Res Hum Retroviruses; 2001 Mar; 17(4):337-48. PubMed ID: 11242520
[TBL] [Abstract][Full Text] [Related]
4. Human T-lymphotropic virus type 1 peptides in chimeric and multivalent constructs with promiscuous T-cell epitopes enhance immunogenicity and overcome genetic restriction.
Lairmore MD; DiGeorge AM; Conrad SF; Trevino AV; Lal RB; Kaumaya PT
J Virol; 1995 Oct; 69(10):6077-89. PubMed ID: 7545241
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and conformational properties of an N-linked glycosylated peptide epitope of human T-lymphotropic virus type 1 (HTLV-I).
Conrad SF; Byeon IJ; DiGeorge AM; Lairmore MD; Tsai MD; Kaumaya PT
Biomed Pept Proteins Nucleic Acids; 1995; 1(2):83-92. PubMed ID: 9346859
[TBL] [Abstract][Full Text] [Related]
6. Mapping of immunogenic regions of human T cell leukemia virus type I (HTLV-I) gp46 and gp21 envelope glycoproteins with env-encoded synthetic peptides and a monoclonal antibody to gp46.
Palker TJ; Tanner ME; Scearce RM; Streilein RD; Clark ME; Haynes BF
J Immunol; 1989 Feb; 142(3):971-8. PubMed ID: 2563272
[TBL] [Abstract][Full Text] [Related]
7. Identification of novel neutralization-inducing regions of the human T cell lymphotropic virus type I envelope glycoproteins with human HTLV-I-seropositive sera.
Desgranges C; Souche S; Vernant JC; Smadja D; Vahlne A; Horal P
AIDS Res Hum Retroviruses; 1994 Feb; 10(2):163-73. PubMed ID: 8198868
[TBL] [Abstract][Full Text] [Related]
8. Induction of antibody responses that neutralize human T-cell leukemia virus type I infection in vitro and in vivo by peptide immunization.
Tanaka Y; Tanaka R; Terada E; Koyanagi Y; Miyano-Kurosaki N; Yamamoto N; Baba E; Nakamura M; Shida H
J Virol; 1994 Oct; 68(10):6323-31. PubMed ID: 8083972
[TBL] [Abstract][Full Text] [Related]
9. Identification of new epitopes recognized by human monoclonal antibodies with neutralizing and antibody-dependent cellular cytotoxicity activities specific for human T cell leukemia virus type 1.
Kuroki M; Nakamura M; Itoyama Y; Tanaka Y; Shiraki H; Baba E; Esaki T; Tatsumoto T; Nagafuchi S; Nakano S
J Immunol; 1992 Aug; 149(3):940-8. PubMed ID: 1378869
[TBL] [Abstract][Full Text] [Related]
10. Multiple neutralizing B-cell epitopes of human T-cell leukemia virus type 1 (HTLV-1) identified by human monoclonal antibodies. A basis for the design of an HTLV-1 peptide vaccine.
Baba E; Nakamura M; Tanaka Y; Kuroki M; Itoyama Y; Nakano S; Niho Y
J Immunol; 1993 Jul; 151(2):1013-24. PubMed ID: 7687611
[TBL] [Abstract][Full Text] [Related]
11. Induction of CD4+, human T lymphotropic virus type-1-specific cytotoxic T lymphocytes from patients with HAM/TSP. Recognition of an immunogenic region of the gp46 envelope glycoprotein of human T lymphotropic virus type-1.
Jacobson S; Reuben JS; Streilein RD; Palker TJ
J Immunol; 1991 Feb; 146(4):1155-62. PubMed ID: 1704032
[TBL] [Abstract][Full Text] [Related]
12. A peptide-based human T cell leukemia virus type I vaccine containing T and B cell epitopes that induces high titers of neutralizing antibodies.
Baba E; Nakamura M; Ohkuma K; Kira J; Tanaka Y; Nakano S; Niho Y
J Immunol; 1995 Jan; 154(1):399-412. PubMed ID: 7527817
[TBL] [Abstract][Full Text] [Related]
13. Mapping of homologous, amino-terminal neutralizing regions of human T-cell lymphotropic virus type I and II gp46 envelope glycoproteins.
Palker TJ; Riggs ER; Spragion DE; Muir AJ; Scearce RM; Randall RR; McAdams MW; McKnight A; Clapham PR; Weiss RA
J Virol; 1992 Oct; 66(10):5879-89. PubMed ID: 1326649
[TBL] [Abstract][Full Text] [Related]
14. Generation and characterization of monoclonal antibodies against multiple epitopes on the C-terminal half of envelope gp46 of human T-cell leukemia virus type-I (HTLV-I).
Tanaka Y; Yasumoto M; Nyunoya H; Ogura T; Kikuchi M; Shimotohno K; Shiraki H; Kuroda N; Shida H; Tozawa H
Int J Cancer; 1990 Oct; 46(4):675-81. PubMed ID: 1698731
[TBL] [Abstract][Full Text] [Related]
15. Functional conservation of the neutralizing domains on the external envelope glycoprotein of cosmopolitan and melanesian strains of human T cell leukemia/lymphoma virus type I.
Hoshino H; Nakamura T; Tanaka Y; Miyoshi I; Yanagihara R
J Infect Dis; 1993 Dec; 168(6):1368-73. PubMed ID: 7504032
[TBL] [Abstract][Full Text] [Related]
16. Influence of amino acid substitutions on antigenicity of immunodominant regions of the HTLV type I envelope surface gylcoprotein: a study using monoclonal antibodies raised against relevant peptides.
Londos-Gagliardi D; Jauvin V; Armengaut MH; Astier-Gin T; Goetz M; Huet S; Guillemain BJ
AIDS Res Hum Retroviruses; 1999 Jul; 15(10):909-20. PubMed ID: 10408728
[TBL] [Abstract][Full Text] [Related]
17. Epitope mapping of human monoclonal antibodies recognizing conformational epitopes within HTLV type 1 gp46, employing HTLV type 1/2 envelope chimeras.
Hadlock KG; Yang Q; Rowe J; Foung SK
AIDS Res Hum Retroviruses; 2002 Jan; 18(1):57-70. PubMed ID: 11804557
[TBL] [Abstract][Full Text] [Related]
18. Structural and immunogenicity analysis of chimeric B-cell epitope constructs derived from the gp46 and gp21 subunits of the envelope glycoproteins of HTLV-1.
Sundaram R; Beebe M; Kaumaya PT
J Pept Res; 2004 Feb; 63(2):132-40. PubMed ID: 15009534
[TBL] [Abstract][Full Text] [Related]
19. Enhanced immunogenicity of a conformational epitope of human T-lymphotropic virus type 1 using a novel chimeric peptide.
Frangione-Beebe M; Albrecht B; Dakappagari N; Rose RT; Brooks CL; Schwendeman SP; Lairmore MD; Kaumaya PT
Vaccine; 2000 Dec; 19(9-10):1068-81. PubMed ID: 11137241
[TBL] [Abstract][Full Text] [Related]
20. Characterization of monoclonal antibodies directed against the gp46 of human T-cell leukemia virus type I.
Edouard E; Legrand E; Astier-Gin T; Dalibart R; Geoffre S; Dalbon P; Guillemain B; Londos-Gagliardi D
Leukemia; 1994 Apr; 8 Suppl 1():S60-4. PubMed ID: 7512182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
